On July 25, the Food and Drug Administration (FDA) signed a new contract to acquire human fetal tissue for purposes of transplanting into humanized mice.
“…the U.S. Food and Drug Administration (FDA), Office of Acquisitions and Grant Services (OAGS) intends to award a sole source contract to Advanced Bioscience Resources, Inc., ABR is the only company in the U. S. capable of supplying tissues suitable for HM research. No other company or organization is capable of fulfilling the need,” according to the FDA report.
The FDA has created a market for aborted baby parts, by issuing a contract for the purpose of obtaining human fetal tissue to use in mice with human immune systems.
“The Government intends to solicit and negotiate directly with Advanced Bioscience Resources (ABR) Inc. and no solicitation will be issued. The objective is to acquire Tissue for Humanized Mice,” as stated in the FDA report.
“The FDA’s June 13 presolicitation notice contended that Advanced Biosciences Resources was the only organization that could fulfill the new contract,” reported CNS News.
The House Appropriations Committee approved a bill to fund the Department of Health and Human Services for the fiscal year of 2019 in July. The bill includes language prohibiting the federal funding of research using human fetal tissue obtained through abortions.
This language was not included in any of the bills that were passed and signed into law for the 2018 fiscal year.
However, for the bill passed in July by appropriations and for the language to mandate legal action in the 2019 fiscal year, the bill would have to be passed by both the House and Senate and signed into law by President Trump.
Join the conversation as a VIP Member